Lidocaína Aurovitas

Lidocaine Hydrochloride, the active ingredient in Lidocaína Aurovitas, is a local anesthetic (amide type) presented as a sterile solution for epidural, intramuscular and intravenous use. It provides reversible nerve block for surgical and pain‑management procedures in adult patients. GNH USA supplies Lidocaína Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaína Aurovitas is a local anesthetic used in procedures that require temporary nerve blockade. - Epidural procedures: provides localized anesthesia for obstetric or surgical interventions performed via the epidural space. - Intramuscular injections: produces rapid, site‑specific numbness to facilitate painful intramuscular drug administration. - Intravenous regional anesthesia (Bier block): enables safe, reversible anesthesia of a limb during minor orthopedic surgeries. - Pain management: offers short‑term analgesia for acute procedural pain when administered by qualified clinicians.

Lidocaína Aurovitas may cause a range of adverse reactions, most of which are related to its local anesthetic properties.

Common Side Effects: - Transient numbness or tingling at the injection site - Mild hypotension or dizziness - Nausea or metallic taste - Localized swelling or erythema - Headache - Mild pruritus

Serious or Rare Side Effects: - Allergic reactions including rash, urticaria or anaphylaxis - Central nervous system toxicity such as seizures or loss of consciousness - Cardiac arrhythmias or conduction disturbances - Methemoglobinemia - Respiratory depression - Systemic toxicity with CNS and cardiovascular collapse

When using Lidocaína Aurovitas, clinicians should observe several safety measures. - Assess patient allergy: verify no known hypersensitivity to lidocaine or amide‑type anesthetics. - Monitor cardiovascular status: watch for hypotension, bradycardia or arrhythmias during administration. - Use the lowest effective dose: limit systemic exposure to reduce toxicity risk. - Avoid concurrent use with other local anesthetics: prevents additive toxic effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lidocaína Aurovitas can interact with other medicines, altering its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may cause severe cardiotoxicity. - Beta‑blockers: can enhance hypotensive effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Other local anesthetics: additive risk of systemic toxicity. - General anesthetics (e.g., propofol, volatile agents): may potentiate central nervous system depression. - Diuretics: may affect lidocaine plasma levels and renal clearance.